| Identification | Back Directory | [Name]
4,6,12,19-Tetraazadocosane-1,3,7-tricarboxylic acid, 22-[3-[[[2-[[[5-(2-carboxyethyl)-2-hydroxyphenyl]methyl](carboxymethyl)amino]ethyl](carboxymethyl)amino]methyl]-4-hydroxyphenyl]-5,13,20-trioxo-, (3S,7S)- | [CAS]
1366302-52-4 | [Synonyms]
PSMA11
PSMA-HBED-CC
DKFZ-PSMA-11
PSMA-11 trifluoroacetate
HBED-CC-PSMA(1366302-52-4)
4,6,12,19-Tetraazadocosane-1,3,7-tricarboxylic acid, 22-[3-[[[2-[[[5-(2-carboxyethyl)-2-hydroxypheny
4,6,12,19-Tetraazadocosane-1,3,7-tricarboxylic acid, 22-[3-[[[2-[[[5-(2-carboxyethyl)-2-hydroxyphenyl]methyl](carboxymethyl)amino]ethyl](carboxymethyl)amino]methyl]-4-hydroxyphenyl]-5,13,20-trioxo-, (3S,7S)- | [EINECS(EC#)]
246-639-0 | [Molecular Formula]
C44H62N6O17 | [MDL Number]
MFCD29767877 | [MOL File]
1366302-52-4.mol | [Molecular Weight]
946.993 |
| Hazard Information | Back Directory | [Uses]
The prostate-specific membrane antigen (PSMA) has received increased consideration during the past few years as an excellent target for both imaging and therapy of prostate cancer. ?After many years of outstanding preclin. | [storage]
-20°C, protect from light |
|
|